American Vanguard reported a challenging QQ3 2024, with adjusted EBITDA of $2 million on adjusted revenue of $130.7 million, reflecting a significant YoY and QoQ decline driven primarily by the U.S. Aztec granular soil insecticide and Folex cotton defoliant softness, plus non-recurring Dacthal recall charges. GAAP revenue was $118.3 million with gross profit of $17.3 million and a gross margin of 14.6%, down from 29% a year earlier, as Aztec sales deteriorated and Folex faced generic competition. The company recorded a net loss of $25.7 million and an EPS of -0.91 for QQ3. Cash flow showed resilience: operating cash flow was $27.9 million and free cash flow was $26.7 million, aided by working capital improvements. Management reaffirmed full-year EBITDA guidance of $40–$50 million and highlighted that fourth quarter seasonality should provide stronger demand, aided by ongoing execution of a broad transformation program. The transformation aims to lift EBITDA margins toward 15% across the agricultural cycle, supported by accelerated procurement savings, a more streamlined commercial structure, and cost discipline. While the near term remains pressured by generic headwinds and regional softness (notably LatAm/Brazil), the company points to Green Solutions and non-crop strengths, an improving harvest backdrop, and a path to meaningful liquidity and inventory reductions. The outlook hinges on sequential stabilization in demand, successful completion of the transformation, and containment of recall-related costs.